Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613999 | 0.90 | HTR4 (0.47) | HTR4ACHEKDM4ECHRM4CHRM5 | |
| SCHEMBL21473565 | 0.80 | KDM4E (0.58) | HTR4ACHEKDM4ECHRM4CHRM5 | |
| SCHEMBL30017160 | 0.80 | KDM4E (0.58) | HTR4ACHEKDM4ECHRM4CHRM5 | |
| SCHEMBL6774093 | 0.79 | CHRNB4 (0.50) | HTR4ACHEKDM4E | |
| SCHEMBL3373962 | 0.79 | KDM4E (0.69) | HTR4KDM4EMAPTKMT2AHTR3A | |
| SCHEMBL4423936 | 0.77 | HTR4 (0.51) | HTR4ACHEKDM4E | |
| SCHEMBL26651130 | 0.76 | KDM4E (0.62) | HTR4ACHEKDM4EMEN1MAPT | |
| SCHEMBL6336768 | 0.75 | HTR4 (0.62) | HTR4ACHEMEN1KMT2AHTR3A | |
| SCHEMBL5500188 | 0.74 | KDM4E (0.55) | HTR4KDM4EMAPTKMT2AHTR3A | |
| SCHEMBL1614754 | 0.74 | MAPT (0.49) | HTR4KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | FLT4, KDR, TEK | HTR4 2397/4885ACHE 4848/4885KDM4E 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.